PLUS THERAPEUTICS, INC.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
CNSY$0.57-11.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
EXHIBIT INDEX
| Exhibit Number | Exhibit Title | Filed with this Form 10-Q | Incorporated by Reference | ||
| Form | File No. | Date Filed | |||
| 3.1 | Composite Certificate of Incorporation | 10-K | 001-34375 Exhibit 3.1 | 03/11/2016 | |
| 3.2 | Certificate of Amendment to Amended and Restated Certificate | 8-K | 001-34375 Exhibit 3.1 | 05/10/2016 | |
| 3.3 | Certificate of Amendment to Amended and Restated Certificate | 8-K | 001-34375 Exhibit 3.1 | 05/23/2018 | |
| 3.4 | Certificate of Amendment to Amended and Restated Certificate | 8-K | 001-34375 Exhibit 3.1 | 07/29/2019 | |
| 3.5 | Certificate of Amendment to Amended and Restated Certificate | 8-K | 001-34375 Exhibit 3.1 | 08/06/2019 | |
| 3.6 | Certificate of Amendment to Amended and Restated Certificate | 8-K | 001-34375 Exhibit 3.1 | 04/28/2023 | |
| 3.7 | Certificate of Amendment to the Certificate of Incorporation, as amended | 8-K | 001-34375 Exhibit 3.1 | 05/02/2025 | |
| 3.8 | Amended and Restated Bylaws of Plus Therapeutics, Inc. | 8-K | 001-34375Exhibit 3.1 | 09/21/2021 | |
| 3.9 | Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock | 8-K | 001-34375Exhibit 3.1 | 11/28/2017 | |
| 3.10 | Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock | 8-K | 001-34375Exhibit 3.1 | 07/25/2018 | |
| 4.1 | Description of Securities | 10-K | 001-34375Exhibit 4.1 | 03/30/2020 | |
| 4.2 | Form of Common Stock Certificate | 10-K | 001-34375Exhibit 4.33 | 03/09/2018 | |
| 4.3 | Form of Pre-Funded Warrant | 8-K | 001-34375Exhibit 4.1 | 05/09/2024 | |
| 4.4 | Form of Amendment and Restatement of the May 2024 Series A Warrant | 10-Q | 011-34375Exhibit 4.7 | 08/14/2024 | |
| 4.5 | Form of Amendment and Restatement of the May 2024 Series B Warrant | 10-Q | 011-34375Exhibit 4.8 | 08/14/2024 | |
| 4.6 | Form of Amended and Restated Series B Common Stock Purchase Warrant | 8-K | 011-34375Exhibit 4.1 | 06/17/2025 | |
| 4.7 | Form of Pre-Funded Warrant | 8-K | 011-34375Exhibit 4.1 | 02/18/2025 | |
| 4.8 | Form of Warrant issued pursuant to the Securities Purchase and Exchange Agreement, dated February 13, 2025, by and | 8-K | 001-34375Exhibit 4.2 | 02/18/2025 | |
| among Plus Therapeutics, Inc. and the purchasers named therein | ||||
| 4.9 | Form of Pre-Funded Warrant | 8-K | 001-34375Exhibit 4.1 | 03/04/2025 |
| 4.10 | Form of Series A Common Stock Purchase Warrant | 8-K | 001-34375Exhibit 4.2 | 03/04/2025 |
| 4.11 | Form of Series B Common Stock Purchase Warrant | 8-K | 001-34375Exhibit 4.3 | 03/04/2025 |
| 4.12 | Form of A&R Series B Warrant | 8-K | 001-34375Exhibit 4.1 | 06/17/2025 |
| 10.1 | Securities Purchase and Exchange Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers named therein | 8-K | 001-34375Exhibit 10.1 | 02/18/2025 |
| 10.2 | Form of Secured Convertible Note for Funding Notes issued pursuant to the Securities Purchase and Exchange Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers names therein | 8-K | 001-34375Exhibit 10.2 | 02/18/2025 |
| 10.3 | Form of Secured Convertible Note for Exchange Notes issued pursuant to the Securities Purchase and Exchange Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers names therein | 8-K | 001-34375Exhibit 10.3 | 02/18/2025 |
| 10.4 | Security Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc., CNSide Diagnostics, LLC and Iroqouis Master Fund Ltd., as collateral agent for the purchasers names therein | 8-K | 001-34375Exhibit 10.4 | 02/18/2025 |
| 10.5 | Subsidiary Guarantee, dated as of February 13, 2025, by and among CNSide Diagnostics, LLC and the purchasers named therein | 8-K | 001-34375Exhibit 10.5 | 02/18/2025 |
| 10.6 | Registration Rights Agreement, dated February 13, 2025, by and among Plus Therapeutics, Inc. and the purchasers named therein | 8-K | 001-34375Exhibit 10.6 | 02/18/2025 |
| 10.7 | Second Amendment to Securities Purchase Agreement, dated May 5, 2024, as amended on May 9, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein | 8-K | 001-34375Exhibit 10.7 | 02/18/2025 |
| 10.8 | Securities Purchase Agreement, dated as of March 4, 2025 | 8-K | 001-34375Exhibit 10.1 | 03/04/2025 |
| 10.9 | Registration Rights Agreement, dated as of March 4, 2025 | 8-K | 001-34375Exhibit 10.2 | 03/04/2025 |
| 10.10 | First Amendment to Securities Purchase and Exchange Agreement, dated as of March 4, 2025 | 8-K | 001-34375Exhibit 10.3 | 03/04/2025 |
| 10.11 | Form of Letter Agreement | 8-K | 001-34375Exhibit 10.1 | 06/17/2025 |
| 10.12 | Purchase Agreement, dated June 17, 2025, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC | 8-K | 001-34375Exhibit 10.1 | 06/20/2025 | |
| 10.13 | Registration Rights Agreement, dated June 17, 2025, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC | 8-K | 001-34375Exhibit 10.2 | 06/20/2025 | |
| 10.14 | Form of Support Letter, dated July 11, 2025, by and between Plus Therapeutics, Inc. and certain holders | S-1 | 333-289526Exhibit 10.41 | 08/12/2025 | |
| 10.15 | Amended & Restated 2020 Stock Incentive Plan, amended August 7, 2025 | X | |||
| 31.1* | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-1.04(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
| 31.2* | Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
| 32.1* | Certifications Pursuant to 18 U.S.C. Section 1350/ Securities Exchange Act Rule 13a-14(b), as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002 | ||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | X | |||
| 101.SCH | Inline XBRL Schema Document | X | |||
| 101.CAL | Inline XBRL Calculation Linkbase Document | X | |||
| 101.DEF | Inline XBRL Definition Linkbase Document | X | |||
| 101.LAB | Inline XBRL Label Linkbase Document | X | |||
| 101.PRE | Inline XBRL Presentation Linkbase Document | X | |||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | X | |||
- In accordance with Item 601(b)(32)(ii) of Regulation S‑K and SEC Release No. 34‑47986, the certifications furnished in Exhibits 31.1, 31.2 and 32.1 hereto are deemed to accompany this Form 10‑Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the Company specifically incorporates them by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| PLUS THERAPEUTICS, INC. | ||
| By: | /s/ Marc H. Hedrick | |
| Dated: August 14, 2025 | Marc H. Hedrick | |
|---|---|---|
| President & Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) | ||
| By: | /s/ Andrew Sims | |
| Dated: August 14, 2025 | Andrew Sims | |
| Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer and Principal Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.